Skip to main content

Table 2 Circulating concentrations of osteoprotegerin and breast cancer risk by hormone-receptor subtype: EPIC cohort breast cancer nested case-control study

From: Osteoprotegerin and breast cancer risk by hormone receptor subtype: a nested case-control study in the EPIC cohort

 

Tertiles

   

1

2

3

   

Cut points (ng/mL)

<0.18

0.18 - <0.22

≥0.22

p trend a

RRlog2 b

p het c

ER+/PR+

 Cases/controls

342/312

297/308

290/309

   

 RR (95% CI)

Ref.

0.84 (0.65-1.07)

0.81 (0.61-1.08)

0.27

0.85 (0.63-1.14)

0.02

ER+

 Cases/controls

559/510

519/544

544/568

   

 RR (95% CI)

Ref.

0.84 (0.70-1.02)

0.84 (0.68-1.04)

0.18

0.86 (0.68-1.08)

0.02

ER–/PR–

 Cases/controls

82/96

78/96

98/66

   

 RR (95% CI)

Ref.

1.12 (0.68-1.83)

2.39 (1.35-4.23)

0.04

1.89 (1.03-3.47)

 

ER–

 Cases/controls

139/160

117/125

130/101

   

 RR (95% CI)

Ref.

1.22 (0.83-1.83)

1.93 (1.24-3.02)

0.03

1.69 (1.05-2.74)

 
  1. Conditional logistic regression models adjusted for ages at menarche (≤12, 13, 14, ≥15, missing), menopause (<44, 44-47, 48-50, 51-52, 53-54, ≥55, missing), first full-term pregnancy (no FTP, <25, 25-30, ≥30, missing), number of full-term pregnancies (0, 1, 2, ≥3, missing), and BMI (kg/m2, continuous)
  2. a p trend based on log2-transformed OPG concentration
  3. bRR for a one-unit change in log2-transformed OPG
  4. c p heterogeneity comparing ER+/PR+ to ER–/PR– and ER+ to ER– subtypes, based on log2-transformed OPG concentration
Back to article page

BMC Medicine

ISSN: 1741-7015

Contact us